A clinical trial has backed the safety and efficacy of one of Novo Nordisk's weight-loss medicines in children as young as six, showing a significant drop in body mass index (BMI).
Fresh from reporting encouraging results with its oral weight-loss drug, Terns Pharma has moved swiftly ahead with a public offering, seeking to raise upwards of $125 million to fund additi
Swiss start-up Haya Therapeutics has formed a partnership with Eli Lilly – worth up to $1 billion – to look for new therapies for obesity in non-coding DNA.
Eli Lilly has launched new single-dose 2.5mg and 5.0mg vials of its obesity drug Zepbound in a move that it said would make it easier for people paying for the drug out-of-pocket to afford
A study has found a higher risk of suicidal thoughts in users of Novo Nordisk's GLP-1 agonist-based drugs for diabetes and obesity, even though regulators in the US and EU concluded there w
Eli Lilly's latest clinical readout for dual GIP/GLP-1 agonist tirzepatide is a big one, with data suggesting the drug can reduce the risk of developing type 2 diabetes in overweight and ob
AstraZeneca has revealed the data for Imfinzi in muscle-invasive bladder cancer (MIBC) that it hopes will be enough to secure FDA approval – although the jury is out on that.
The Life Sciences Generative AI Council aims to bring together the best minds in pharma, academia, and technology to advance the use of GenAI in life sciences R&D, seeking through pinpo